Mia's Feed
Medical News & Research

FDA Approves Gilead's Biannual Injection for HIV Prevention in the US

FDA Approves Gilead's Biannual Injection for HIV Prevention in the US

Share this article

The FDA has approved Gilead's groundbreaking twice-yearly injection to prevent HIV, offering a powerful new tool in the fight against the virus with over 99.9% efficacy demonstrated in clinical trials.

2 min read

On June 18, 2025, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences' innovative twice-yearly injection designed to prevent HIV transmission. This landmark approval marks a significant advancement in HIV prevention strategies, providing a long-lasting alternative to daily oral medications. The injectable treatment, marketed as Yeztugo and containing the drug lenacapavir, has demonstrated in clinical trials the ability to reduce the risk of HIV infection by over 99.9% in adults and adolescents, effectively functioning like a powerful vaccine.

Pre-exposure prophylaxis (PrEP) medications have been available for over ten years, mainly in pill form requiring daily intake. However, adherence challenges have limited their impact on reducing global infection rates. This new injectable offers a promising solution by minimizing the need for frequent dosing, which could enhance compliance and broadening prevention efforts.

Despite the excitement surrounding this development, concerns about accessibility remain. Although Gilead has not announced official pricing, analysts estimate the US launch price could reach up to $25,000 annually. HIV activists are calling for the price to be significantly lowered—around $25 per year—to ensure widespread access and help end the HIV pandemic.

The approval comes at a time when U.S. funding for HIV treatment and prevention programs has been cut by the current administration, both domestically and internationally, raising questions about equitable access to this promising new tool. Still, health experts believe that this innovation could transform HIV prevention, reducing new infections and saving lives.

Source: https://medicalxpress.com/news/2025-06-gilead-yearly-hiv.html

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

Pediatrician Warns that Banning Fluoride in Public Water Systems Jeopardizes Kids' Oral Health in Rural and Low-Income Communities

Legislation banning fluoride in public water supplies threatens to increase dental cavities among children in rural and low-income communities, warns pediatrician. Experts emphasize the importance of water fluoridation for preventing childhood cavities, especially where dental care access is limited.

Addressing Childhood Chronic Pain: The Role of School Nurses in Management and Care

A significant portion of children suffer from chronic pain impacting their daily lives. Training school nurses and community health providers in pain management strategies offers a promising solution to improve access and long-term outcomes for affected children.

Innovative Algorithm Enhances Vascular Design for 3D Bioprinted Hearts

A new algorithm developed at Stanford significantly speeds up the design of complex vascular networks for 3D bioprinted hearts, paving the way for improved organ manufacturing and regenerative medicine.